

## UNOFFICIAL TRANSLATION

The formal official document is in Japanese



## Summary of Consolidated Financial Results for the Fiscal Year ended September 30, 2025 (Japanese Accounting Standards)

November 11, 2025

Listed Company Name: MTI Ltd.

Listing Exchanges: Tokyo Stock Exchange

Securities Code: 9438

URL: <https://ir.mti.co.jp/eng/>

Representative: Toshihiro Maeta, President and Chief Executive Officer

Contact: Hiroshi Matsumoto, Senior managing Director

Phone: +81-3-5333-6323

Scheduled date of annual meeting of shareholders: December 20, 2025

Scheduled date to submit the Securities Report (Yuka Shoken Houkokusho): December 19, 2025

Scheduled date of dividend payment: December 22, 2025

Supplementary documents for financial results: Yes

Financial results briefing: Yes (for securities analysts and institutional investors (online))

(Figures less than one millions of yen are omitted)

## 1. Consolidated financial results for the year ended September 30, 2025

(October 1, 2024 – September 30, 2025)

## (1) Consolidated operating results

(Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the year ended September 30, 2025	29,910	8.1	2,946	23.1	3,027	7.1	3,404	44.0
For the year ended September 30, 2024	27,669	3.2	2,394	702.3	2,827	516.7	2,363	213.8

(Note) Comprehensive income: Year ended September 30, 2025: 3,677 million yen, (49.0%)  
Year months ended September 30, 2024: 2,467 million yen, (216.8%)

	Net income per share	Net income per share/diluted	Return on Equity	Return on Assets	Net income
	Yen	Yen	%	%	%
For the year ended September 30, 2025	61.62	61.55	20.1	9.6	9.8
For the year ended September 30, 2024	43.05	43.02	16.1	9.6	8.7

(Reference) Equity in earnings (losses) of affiliates: Year ended September 30 2025: 107 millions of yen  
Year ended September 30 2024: 534 millions of yen

## (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Year ended September 30, 2025	33,347	22,446	55.2	331.86
Year ended September 30, 2024	29,686	19,144	52.0	280.50

(Reference) Shareholders' equity: Year ended September 30, 2025: 18,413 millions of yen  
Year ended September 30, 2024: 15,446 millions of yen

## (3) Consolidated cash flows

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalent
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
For the year ended September 30, 2025	5,661	(1,706)	(943)	17,816
For the year ended September 30, 2024	4,131	(1,368)	(1,637)	14,828

## 2. Dividends

	Dividend per share					Amount of dividends paid (Total)	Dividend ratio (Consolidated)	Dividends on equity (Consolidated)
	End of first quarter	End of second period	End of third quarter	Year end	Annual			
For the year ended September 30, 2024	Yen –	Yen 8.00	Yen –	Yen 9.00	Yen 17.00	938	% 39.5	% 6.4
For the year ended September 30, 2025	–	9.00	–	10.00	19.00	1,056	30.8	6.2
For the year ending September 30, 2026 (forecast)	–	10.00	–	10.00	20.00		58.1	

\* The dividend ratio for the fiscal year ending September 30, 2026 is calculated based on the median value of the projected profit attributable to owners of parent.

3. Forecast for consolidated financial results for the fiscal year ending September 30, 2026  
(October 1, 2025 – September 30, 2026)

(Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
For the first half	15,000	0.8	1,400 ~ 1,600	(14.6) ~ (2.4)	1,450 ~ 1,650	(15.8) ~ (4.2)	780 ~ 920	(55.6) ~ (47.6)	14.06 ~ 16.58
Full year	31,000	3.6	3,100 ~ 3,500	5.2 ~ 18.8	3,100 ~ 3,500	2.4 ~ 15.6	1,770 ~ 2,050	(48.0) ~ (39.8)	31.90 ~ 36.95

\* Notes

(1) Important changes of subsidiaries during the term (changes in specified subsidiaries resulting in change in scope of consolidation): Not applicable

New: –

Exception: –

(2) Changes in accounting policies and changes or restatement of accounting estimates

(i) Changes in accounting policies due to the modification in accounting methods:

Applicable

(ii) Changes in accounting policies other than (i):

Not applicable

(iii) Changes in accounting estimates:

Not applicable

(iv) Restatement:

Not applicable

(3) Number of outstanding shares (common shares)

(i) Number of outstanding shares at the end of period (including treasury shares):

9/25: 60,435,200 shares

9/24: 61,429,600 shares

(ii) Number of treasury shares at the end of period

9/25: 4,947,414 shares

9/24: 6,361,273 shares

(iii) Average number of shares during the period

9/25: 55,247,865 shares

9/24: 54,913,627 shares

(Reference) Summary of financial results

1. Nonconsolidated financial results for the year ended September 30, 2025

(From October 1, 2024 - September 30, 2025)

(1) Nonconsolidated operating results

(Percentages are shown as year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the year ended September 30, 2025	23,291	5.7	2,301	(2.0)	2,123	(26.6)	3,045	63.1
For the year ended September 30, 2024	22,028	6.1	2,348	59.0	2,892	279.8	1,867	(22.4)

	Net income per share	Fully diluted net income per share
	Yen	Yen
For the year ended September 30, 2025	54.92	54.86
For the year ended September 30, 2024	33.88	33.85

(2) Nonconsolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
For the year ended September 30, 2025	30,337	21,343	70.4	383.28
For the year ended September 30, 2024	27,377	18,539	67.6	335.04

(Reference) Shareholders' equity

As of September 30, 2025: 21,343 millions of yen As of September 30, 2024: 18,516 millions of yen

\* Status of review

Financial results is out of audit.

\* Cautionary statement with respect to forward-looking statements

The forward-looking statements included in this material are based on the Company's judgments, assumptions, and convictions based on information available to the Company at the time of publication of this document and may differ materially from actual results for a range of factors, including conditions of Japanese and overseas economies, changes in the situation of operations in Japan and overseas, and uncertainties and potential risks inherent in forward-looking statements. The risks and uncertainties include unforeseeable effects of future events. For the assumptions underlying the forecasts and other notice on the use of earnings forecasts, please refer to "(4) Future outlook" on page 4 in the accompanying material.

The company plans to hold an online earnings briefing (Japanese) for institutional investors and analysts on Wednesday, November 12, 2025. The materials for the earnings briefing will be posted on the company's IR website.

## Accompanying materials – Contents

1. Overview of operating results.....	2
(1) Overview of operating results for the current fiscal year.....	2
(2) Overview of financial position for the current fiscal year.....	3
(3) Overview of cash flow for the current fiscal year.....	4
(4) Future outlook.....	4
2. Basic policy for the selection of accounting standard.....	6
3. Consolidated financial statements and important notes.....	7
(1) Consolidated balance sheet.....	7
(2) Consolidated statement of income and comprehensive income.....	9
(3) Consolidated statement of changes in shareholders' equity.....	11
(4) Consolidated statement of cash flows.....	13
(5) Notes to the Consolidated Financial statement.....	15

## 1. Overview of operating results

### (1) Overview of operating results for the current fiscal year

The Group has been actively engaged in the healthcare business and the school DX business, both of which are expected to expand in the future, in order to enhance its corporate value over the medium- to long-term.

Net sales increased to ¥29,910 million (up 8.1% year-on-year), mainly due to sales growth in the healthcare and school DX businesses, and gross profit increased to ¥22,223 million (up 8.9% year-on-year) due to higher net sales.

Operating income increased to ¥2,946 million (up 23.1% year-on-year), as the rise in gross profit more than offset the increase in selling, general and administrative expenses (SG&A), which was mainly due to higher advertising and promotion expenses.

Ordinary income increased to ¥3,027 million (up 7.1% year-on-year). In the previous fiscal year, equity in earnings of affiliates amounted to ¥534 million, mainly reflecting a special gain recorded by Shobunsha Holdings, Inc., an equity-method affiliate. In the current fiscal year, equity in earnings of affiliates totaled ¥107 million, resulting in only a modest increase in ordinary income.

Profit attributable to owners of parent increased significantly to ¥3,404 million (up 44.0% year-on-year), mainly due to a substantial increase in special gains associated with refunded consumption tax and a decrease in income tax adjustments resulting from the recognition of deferred tax assets at consolidated subsidiaries.

### Consolidated operating results

(Period from October 1, 2024 to September 30, 2025)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2024	Change	
			Amount	Percentage
	Millions of yen	Millions of yen	Millions of yen	%
Net sales	29,910	27,669	+2,241	+8.1
Cost of sales	7,687	7,264	+423	+5.8
Gross profit	22,223	20,404	+1,818	+8.9
SG&A	19,276	18,010	+1,266	+7.0
Operating income	2,946	2,394	+551	+23.1
Ordinary income	3,027	2,827	+199	+7.1
Profit attributable to Owners of parent	3,404	2,363	+1,040	+44.0

### Breakdown of SG&A

(Period from October 1, 2024 to September 30, 2025)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2024	Change	
			Amount	Percentage
	Millions of yen	Millions of yen	Millions of yen	%
Total	19,276	18,010	+1,266	+7.0
Advertising expenses	3,661	2,800	+860	+30.7
Personnel expenses	7,504	7,276	+227	+3.1
Commission fee	3,113	2,871	+242	+8.5
Subcontract expenses	1,734	1,738	Δ3	Δ0.2
Depreciation	1,224	1,359	Δ135	Δ10.0
Other	2,039	1,964	+75	+3.8

Operating results by segment are as follows.

**(i) Content business**

The content business includes B2C monthly billing services (excluding the *Luna-Luna* healthcare service for women and the *CARADA medica* health Q&A service in cooperation with healthcare professionals) and the B2B original comic distribution business that offers original comic content to comic distributors.

The number of monthly paid subscribers in this business expanded to 3.24 million (an increase of 0.17 million from the end of September 2024), mainly due to the impact of acquiring a company engaged in music distribution and other services, as well as strong new subscriptions through carrier shops. Excluding the impact of the acquisition, the number of fee-paying subscribers increased slightly, as subscriptions to security-related apps such as *AdGuard* continued to grow.

Net sales increased to ¥17,314 million (up 2.2% year-on-year).

Operating income decreased slightly to ¥4,270 million (down 1.2% year-on-year), mainly due to higher advertising and promotion expenses associated with the acquisition of new subscribers for *AdGuard* and other services.

**(ii) Healthcare business**

The healthcare business includes B2C monthly billing services under the *Luna-Luna* and *CARADA medica* brands and B2B and B2B2C healthcare services for medical institutions and local governments, such as the cloud drug record service, the maternal health record book app and the childcare DX service.

The number of monthly paid subscribers in this business was 0.47 million (a decrease of 0.04 million from the end of September 2024). The number of stores using the cloud-based medication history service expanded significantly to 3,811 as of the end of September 2025 (an increase of 1,283 from the end of September 2024), driven by our focus on expanding installations at medium- and large-sized dispensing pharmacies.

Net sales increased significantly to ¥6,676 million (up 21.8% year-on-year), mainly due to growth in sales of the Cloud-based medication history service.

Although earnings from the cloud-based medication history service increased, the segment recorded an operating loss of ¥80 million (compared with a profit of ¥352 million in the previous fiscal year), mainly due to higher development costs for pharmacy DX and childcare DX services.

**(iii) School DX business**

The school DX business includes school DX business developed for educational institutions by the consolidated subsidiary Motivation Works Inc..

Net sales increased significantly to ¥1,890 million (up 53.3% year-on-year), mainly due to an increase in monthly service fees following the expansion of the cumulative number of schools using the cloud-based school affairs support system *BLEND* to 1,067 schools as of April 2025 (an increase of 292 schools from April 2024), as well as the recording of initial development sales for public schools.

Operating income increased substantially to ¥550 million (compared with a loss of ¥66 million in the previous fiscal year), mainly due to the significant rise in net sales.

**(iv) Other business**

Other business includes the B2B AI business operated by Automagi Inc., a consolidated subsidiary, and the corporate DX support business and solution business.

Net sales increased to ¥5,539 million (up 3.5% year-on-year), mainly due to steady orders in the corporate DX support business.

Operating income increased significantly to ¥949 million (up 216.3% year-on-year), reflecting both higher net sales and a reduction in selling, general and administrative expenses resulting from the downsizing of unprofitable businesses.

**(2) Overview of financial position for the current fiscal year**

As of the end of the fiscal year under review, total assets increased ¥3,661 million from the end of September 2024, to ¥33,347 million.

In the assets section, current assets increased by ¥3,060 million, mainly due to an increase in cash and deposits, while non-current assets increased by ¥601 million, primarily reflecting higher investment securities and software.

In the liabilities section, current liabilities increased by ¥1,122 million, mainly due to an increase in income taxes payable and accounts payable, while non-current liabilities decreased by ¥762 million, primarily due to a decrease in long-term borrowings.

In the net assets section, despite the payment of dividends, net assets increased by ¥3,301 million, mainly due to the recording of ¥3,404 million in net income attributable to owners of the parent and capital increases at consolidated subsidiaries.

### (3) Overview of cash flow position for the current fiscal year

As of the end of the fiscal year under review, cash and cash equivalents increased by ¥2,987 million from the end of September 2024 to ¥17,816 million. Cash flow by activity and principal factors in the fiscal year under review were as follows.

Net cash provided by operating activities resulted in a net inflow of ¥5,661 million (compared with a net inflow of ¥4,131 million in the previous fiscal year), mainly due to income before income taxes and depreciation and amortization.

Net cash used in investing activities resulted in a net outflow of ¥1,706 million (compared with a net outflow of ¥1,368 million in the previous fiscal year), mainly due to the acquisition of intangible assets, primarily software.

Net cash used in financing activities resulted in a net outflow of ¥943 million (compared with a net outflow of ¥1,637 million in the previous fiscal year), as repayments of long-term borrowings and dividend payments outweighed proceeds from capital increases and share issuances at consolidated subsidiaries.

### (4) Future outlook

The Company will focus on expanding sales and profits in the healthcare business and school DX business, which are expected to drive future growth. Additionally, in the content business, we will work to maintain profitability by increasing the number of paid subscribers for the security-related app *AdGuard* and expanding our original comics business.

The healthcare business, which the company is pursuing as a medium- to long-term initiative, has significant growth potential. As it enables the establishment of long-term relationships with clients compared with the B-to-C model, it can become a stable, stock-based business.

The company will continue to implement various initiatives to achieve sustained sales growth in this business.

In the cloud-based medication history, interest from dispensing pharmacies remains strong, contributing to sustainable sales and profit growth for this business. We aim to further expand the number of adopting stores by strengthening our collaboration with our partner, Medipal Holdings Corporation. Additionally, to comprehensively promote operational efficiency across dispensing pharmacies, we will actively support the shift of pharmacies to cloud-based systems, including various pharmacy DX solutions offered by the group, thereby driving further earnings growth.

In the childcare DX business, as the government continues to promote the digitalization of maternal and child health information, we will further expand the number of municipalities introducing the *Boshimo* maternal and child health record app. Focusing on these municipalities, we will actively promote the expansion of childcare DX services, while advancing the *Boshimo* platform strategy through the realization of digital collaboration among municipalities, hospitals, and residents. Through these initiatives, we aim to develop childcare DX into one of the core businesses within the healthcare segment that contributes to profits over the medium- to long-term.

In the School DX business, the company aims to achieve sustainable growth by actively expanding operations in response to government-led initiatives promoting DX of school administration at the prefectural level. Demand for the cloud-based school affairs support system *BLEND* remains strong, with the number of schools scheduled to implement the system increasing to 1,067 as of April 2025, a rise of 292 schools compared to April 2024. While our order acquisition activities have traditionally focused on private schools, we are now also placing greater emphasis on expanding orders from public schools to drive further growth in both sales and profit.

[Assumptions for forecast values]

The impact of undetermined new businesses and low-probability mergers and acquisitions in the Group are not taken into account and are not incorporated in the forecast figures. The Company will promptly disclose any deviation between forecasts and results that should be disclosed.

#### Earnings forecast for the six months of the fiscal year ending September 30, 2026 (Period from October 1, 2025 to March 30, 2026)

Consolidated	(Millions of yen)	YoY(%)
Net sales	15,000	+0.8
Operating profit	1,400~1,600	(14.6)~(2.4)
Ordinary profit	1,450~1,650	(15.8)~(4.2)
Profit attributable to owners of parent	780~920	(55.6)~(47.6)

**Earnings forecast for the fiscal year ending September 30, 2026  
(Period from October 1, 2025 to September 30, 2026)**

Consolidated	(Millions of yen)	YoY(%)
Net sales	31,000	+3.6
Operating profit	3,100~3,500	+5.2~+18.8
Ordinary profit	3,100~3,500	+2.4~+15.6
Profit attributable to owners of parent	1,770~2,050	(48.0)~(39.8)

## **2. Basic policy for the selection of accounting standards**

The Group intends to compile its consolidated financial statements based on the Japanese accounting standard for the time being, considering the possibility of comparing the terms of financial statements and performances between companies.

It will adopt the International Financial Reporting Standards (IFRS), factoring in the situations in Japan and abroad.

### 3. Consolidated financial statements and important notes

#### (1) Consolidated balance sheet

(Unit: Thousands of yen)

	Previous fiscal year (As of September 30, 2024)	Current fiscal year (As of September 30, 2025)
<b>Assets</b>		
Current assets		
Cash and deposits	14,828,744	17,816,556
Notes and accounts receivable - trade, and contract assets	4,183,929	4,085,621
Advance payments to suppliers	256,743	195,177
Prepaid expenses	446,709	674,848
Accounts receivable - other	139,531	195,437
Income taxes refund receivable	141,435	17,354
Other	186,631	244,691
Allowance for doubtful accounts	(31,173)	(17,046)
<b>Total current assets</b>	<b>20,152,552</b>	<b>23,212,641</b>
Non-current assets		
Property, plant and equipment		
Facilities attached to buildings	320,518	327,165
Accumulated depreciation	(249,532)	(252,988)
Facilities attached to buildings, net	70,986	74,176
Vehicles	200	382
Accumulated depreciation	(152)	(244)
Vehicles, net	48	137
Tools, furniture and fixtures	660,825	703,166
Accumulated depreciation	(528,772)	(558,172)
Tools, furniture and fixtures, net	132,053	144,994
<b>Total property, plant and equipment, net</b>	<b>203,088</b>	<b>219,308</b>
Intangible assets		
Software	1,929,051	2,127,980
Goodwill	27,139	61,788
Customer-related assets	70,200	58,555
Other	249,419	227,530
<b>Total intangible assets</b>	<b>2,275,810</b>	<b>2,475,854</b>
Investments and other assets		
Investment securities	4,466,864	4,691,414
Leasehold and guarantee deposits	293,206	280,563
Deferred tax assets	2,248,082	2,393,184
Other	57,550	86,793
Allowance for doubtful accounts	(10,704)	(12,004)
<b>Total investment and other assets</b>	<b>7,054,998</b>	<b>7,439,950</b>
<b>Total non-current assets</b>	<b>9,533,897</b>	<b>10,135,113</b>
<b>Total assets</b>	<b>29,686,449</b>	<b>33,347,754</b>

(Unit: Thousands of yen)

	Previous fiscal year (As of September 30, 2024)	Current fiscal year (As of September 30, 2025)
<b>Liabilities</b>		
Current liabilities		
Account payable-trade	1,100,083	1,020,636
Current portion of long-term borrowings	737,500	737,500
Accounts payable - other	1,331,851	1,569,951
Accrued expenses	620,321	673,914
Income taxes payable	94,542	894,150
Accrued consumption taxes	191,089	213,232
Contract liabilities	2,667,056	2,726,348
Provision for bonuses for directors	40,852	48,134
Other	168,220	190,320
Total current liabilities	6,951,519	8,074,190
Non-current liabilities		
Long-term borrowings	1,693,750	956,250
Retirement benefit liability	1,828,998	1,825,742
Deferred tax liabilities	-	20,746
Other	67,411	24,699
Total non-current liabilities	3,590,159	2,827,438
Total non-current liabilities	10,541,679	10,901,628
Net assets		
Shareholders' equity		
Share capital	5,310,108	5,511,199
Capital surplus	6,376,663	6,317,535
Retained earnings	6,626,029	8,709,727
Treasury shares	(3,207,144)	(2,596,900)
Total shareholders' equity	15,105,656	17,941,562
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	136,358	195,642
Foreign currency translation adjustment	80,126	57,021
Remeasurements of defined benefit plans	124,327	219,696
Total accumulated other comprehensive income	340,813	472,360
Subscription rights to shares	22,732	-
Non-controlling interests	3,675,568	4,032,203
Total net assets	19,144,770	22,446,125
Total liabilities and net assets	29,686,449	33,347,754

## (2) Consolidated statement of income and consolidated comprehensive income

### Consolidated statement of income

(Unit: Thousands of yen)

	Previous fiscal year (from October 1, 2023 to September 30, 2024)	Current fiscal year (from October 1, 2024 to September 30, 2025)
Net sales	27,669,161	29,910,940
Cost of sales	7,264,252	7,687,798
Gross profit	20,404,908	22,223,141
Selling, general and administrative expenses	18,010,690	19,276,946
Operating income	2,394,217	2,946,195
Non-operating income		
Interest income	376	4,731
Dividend income	3,729	2,294
Share of profit of entities accounted for using equity method	534,915	107,404
Subsidy income, etc.	810	28,442
Other	12,095	22,385
Total non-operating income	551,927	165,258
Non-operating expenses		
Interest expenses	11,289	18,508
Foreign exchange losses	43,322	26,719
Delinquent taxes, etc.	8,082	12,492
Other investment loss	48,395	-
Other	7,837	26,567
Total non-operating expenses	118,927	84,288
Ordinary income	2,827,217	3,027,165
Extraordinary income		
Gain on sale of non-current assets	406	441
Gain on sale of investment securities	-	22,500
Gain on reversal of share acquisition rights	17,129	7,518
Consumption taxes refund	889,323	1,775,356
Gain on transfer of business	15,000	51,000
Gain on liquidation of subsidiaries	-	7,495
Total extraordinary income	921,858	1,864,312
Extraordinary losses		
Loss on sale of non-current assets	-	48
Loss on retirement of non-current assets	11,303	19,400
Impairment losses	261,269	-
Loss on valuation of investment securities	31,672	207,671
Loss on sale of businesses	-	3,113
Other	-	3,089
Total extraordinary losses	304,245	233,323
Net income before income taxes	3,444,831	4,658,154
Income taxes - current	612,678	1,310,874
Income taxes-deferred	382,480	(198,919)
Total income taxes	995,159	1,111,955
Net income	2,449,671	3,546,198
Net income attributable to non-controlling interests	85,751	142,068
Profit attributable to owners of parent	2,363,920	3,404,130

**Consolidated statement of comprehensive income**

(Unit: Thousands of yen)

	Previous fiscal year (from October 1, 2023 to September 30, 2024)	Current fiscal year (from October 1, 2024 to September 30, 2025)
Net income	2,449,671	3,546,198
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,409)	(2,902)
Foreign currency translation adjustment	(17,868)	(23,176)
Remeasurements of defined benefit plans, net of tax	64,733	95,369
Share of other comprehensive income of entities accounted for using equity method	(27,216)	62,256
Total other comprehensive income	18,237	131,546
Comprehensive income	2,467,909	3,677,745
Profit attributable to		
Comprehensive income attributable to owners of parent	2,382,158	3,535,677
Comprehensive income attributable to non-controlling interests	85,751	142,068

### (3) Consolidated statement of changes in equity

Previous fiscal year (from October 1, 2023 to September 30, 2024)

(Unit: Thousands of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at the beginning of the period	5,232,677	6,485,816	5,143,458	(3,230,813)	13,631,139
Changes during period					
Issuance of new shares	77,430	77,430			154,861
Cash dividends			(881,349)		(881,349)
Profit attributable to owners of parent			2,363,920		2,363,920
Acquisitions of treasury shares					-
Cancellation of treasury shares		(23,669)		23,669	-
Changes in ownership interests of consolidated subsidiaries		(162,914)			(162,914)
Transfer to capital surplus from retained earnings					-
Changes during period (net) for items other than shareholders' equity					
Total changes during period	77,430	(109,153)	1,482,570	23,669	1,474,517
Balance at end of period	5,310,108	6,376,663	6,626,029	(3,207,144)	15,105,656

	Accumulated other comprehensive income				Subscription rights to shares	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income			
Balance at the beginning of the period	165,132	97,848	59,594	322,575	59,147	3,570,962	17,583,824
Changes during period							
Issuance of new shares							154,861
Cash dividends							(881,349)
Profit attributable to owners of parent							2,363,920
Acquisitions of treasury shares							-
Cancellation of treasury shares							-
Changes in ownership interests of consolidated subsidiaries							(162,914)
Transfer to capital surplus from retained earnings							-
Changes during period (net) for items other than shareholders' equity	(28,773)	(17,721)	64,733	18,237	(36,414)	104,605	86,429
Total changes during period	(28,773)	(17,721)	64,733	18,237	(36,414)	104,605	1,560,946
Balance at end of period	136,358	80,126	124,327	340,813	22,732	3,675,568	19,144,770

**Current fiscal year (from October 1, 2024 to September 30, 2025)**

(Unit: Thousands of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	5,310,108	6,376,663	6,626,029	(3,207,144)	15,105,656
Changes during period					
Issuance of new shares	201,091	201,091			402,182
Cash dividends			(997,291)		(997,291)
Profit attributable to owners of parent			3,404,130		3,404,130
Acquisitions of treasury shares				(53)	(53)
Cancellation of treasury shares		(610,297)		610,297	-
Changes in ownership interests of consolidated subsidiaries		26,937			26,937
Transfer to capital surplus from retained earnings		323,140	(323,140)		-
Changes during period (net) for items other than shareholders' equity					
Total changes during period	201,091	(59,128)	2,083,698	610,243	2,835,906
Balance at end of period	5,511,199	6,317,535	8,709,727	(2,596,900)	17,941,562

	Accumulated other comprehensive income				Subscription rights to shares	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income			
Balance at the beginning of the period	136,358	80,126	124,327	340,813	22,732	3,675,568	19,144,770
Changes during period							
Issuance of new shares							402,182
Cash dividends							(997,291)
Profit attributable to owners of parent							3,404,130
Acquisitions of treasury shares							(53)
Cancellation of treasury shares							-
Changes in ownership interests of consolidated subsidiaries							26,937
Transfer to capital surplus from retained earnings							-
Changes during period (net) for items other than shareholders' equity	59,283	(23,105)	95,369	131,546	(22,732)	356,634	465,448
Total changes during period	59,283	(23,105)	95,369	131,546	(22,732)	356,634	3,301,354
Balance at end of period	195,642	57,021	219,696	472,360	-	4,032,203	22,446,125

#### (4) Consolidated statement of cash flows

(Unit: Thousands of yen)

	Previous fiscal year (from October 1, 2023 to September 30, 2024)	Current fiscal year (from October 1, 2024 to September 30, 2025)
<b>Cash flows from operating activities</b>		
Net income before income taxes	3,444,831	4,658,154
Depreciation	1,531,935	1,310,284
Impairment losses	261,269	-
Loss (gain) on sale of businesses	(15,000)	(47,886)
Amortization of goodwill	177,291	37,755
Increase (decrease) in allowance for doubtful accounts	(2,768)	(12,827)
Increase (decrease) in liabilities for retirement benefits	146,097	161,485
Interest income and dividends income	(4,105)	(7,026)
Interest expenses	11,289	18,508
Share of loss (profit) of investments accounted for using the equity method	(534,915)	(107,404)
Loss (gain) on sale of fixed assets	(406)	(393)
Loss on retirement of non-current assets	11,303	19,400
Loss (gain) on sale of investment securities	-	(22,500)
Loss (gain) on valuation of investment securities	31,672	207,671
Gain on reversal of share acquisition rights	(17,129)	(7,518)
Decrease (increase) in trade receivables	9,895	94,974
Decrease (increase) in advance payments to suppliers	(42,567)	61,555
Decrease (increase) in prepaid expenses	(32,645)	(233,332)
Increase (decrease) in accounts receivable (- indicates increase)	(7,678)	(55,905)
Increase (decrease) in trade payables	79,862	(76,878)
Increase (decrease) in accounts payable - other (- indicates decrease)	51,295	212,667
Increase (decrease) in accrued expenses	120,336	55,113
Increase and decrease in consumption taxes receivable or payable	(37,018)	14,265
Other	255,283	(44,589)
Subtotal	5,438,127	6,235,574
Interest and dividends received	31,053	33,974
Interest paid	(11,289)	(18,508)
Income taxes refund (paid)	(1,326,559)	(589,378)
Cash flows from operating activities	4,131,332	5,661,660

(Unit: Thousands of yen)

	Previous fiscal year (from October 1, 2023 to September 30, 2024)	Current fiscal year (from October 1, 2024 to September 30, 2025)
<b>Cash flows from investing activities</b>		
Purchase of property and equipment	(86,675)	(85,115)
Proceeds from sales of property and equipment	406	1,246
Purchase of intangible assets	(1,303,429)	(1,279,255)
Purchase of investment securities	-	(200,620)
Proceeds from the sale of investment securities	-	30,000
Purchase of shares of subsidiaries and associates	-	(103,900)
Payments for acquisition of businesses	-	(30,000)
Proceeds from transfer of business	15,000	55,921
Payment for acquisition of subsidiaries resulting in change in scope of consolidation	-	(99,000)
Other	5,722	4,142
Cash flows from investing activities	(1,368,974)	(1,706,580)
<b>Cash flows from financing activities</b>		
Repayment of long-term borrowings	(747,600)	(737,500)
Proceeds from issuance of shares	135,576	386,968
Acquisition of treasury shares	-	(53)
Proceeds from share issuance to non-controlling shareholders	-	687,785
Repayments to non-controlling shareholders	(980)	(2,940)
Cash dividends paid	(881,349)	(997,291)
Dividends paid to non-controlling interests	(980)	-
Payment for acquisition of subsidiaries resulting in no change in scope of consolidation	(142,100)	(780,000)
Proceeds from sale of subsidiaries resulting in no change in scope of consolidation	-	500,000
Cash flows from financing activities	(1,637,433)	(943,031)
Effect of exchange rate change on cash and cash equivalents	(17,094)	(24,236)
Increase (decrease) in cash and cash equivalents	1,107,828	2,987,811
Cash and cash equivalents at the beginning of the period	13,720,915	14,828,744
Cash and cash equivalents at end of the period	14,828,744	17,816,556

## (5) Notes to Consolidated Financial Statements

(Notes regarding the assumption of a going concern)

There are no applicable items.

(Changes in accounting policies)

(Application of Accounting Standards such as 'Income Taxes - Current')

The "Accounting Standard for Income Taxes - Current, etc." (ASBJ Statement No. 27, October 28, 2022), the "Accounting Standard for Presentation of Comprehensive Income" (ASBJ Statement No. 25, October 28, 2022), and the "Implementation Guidance on Accounting Standard for Tax Effect Accounting" (ASBJ Guidance No. 28, October 28, 2022) have been applied from the beginning of the current consolidated fiscal year. There is no impact on the consolidated financial statements as a result of this change in accounting policy.

In addition, regarding the revision related to the treatment in consolidated financial statements of deferred tax on gains or losses arising from the sale of shares of subsidiaries among consolidated companies, the 2022 revised application guidelines have been applied from the beginning of the current consolidated fiscal year. There is no impact on the consolidated financial statements as a result of this change in accounting policy.

(Segment Information, etc.)

(Segment Information)

### 1 Overview of Reportable Segments

#### (1) Method for determining reportable segments

The reportable segments of our group are those components for which separate financial information is available and which are regularly reviewed by the Board of Directors for the purpose of making decisions regarding the allocation of management resources and evaluating performance.

Our group is composed of segments based on business divisions and service categories, and we have designated four reportable segments: the "Content Business," the "Healthcare Business," the "School DX Business," and "Other Businesses."

#### (2) Types of finished goods and services belonging to each reportable segment

The "Content Business" segment includes BtoC monthly subscription services (excluding the women's healthcare service "LunaLuna" and the medical consultation service "Karada Medica"), as well as the original comic business, which provides original comic works to BtoB comic distribution service providers.

The "Healthcare Business" includes BtoC-type monthly subscription services such as "LunaLuna" and "Karada Medica," as well as BtoB and BtoBtoC-type healthcare services provided to medical institutions and local governments (such as cloud-based medication history, maternal and child health record apps, and child-rearing DX, etc.).

The "school DX business" includes the school DX business developed by the consolidated subsidiary Motivation Works Co., Ltd. for educational institutions.

"Other businesses" include the AI business operated by Automagi Inc., a consolidated BtoB subsidiary, as well as corporate DX support and solution businesses conducted by the Company.

#### (3) Matters related to changes in reportable segments

In response to the expansion of the school DX business, and in order to more appropriately understand the performance of each reporting segment within our group, we have reorganized the business classifications for certain transactions that were previously included in the "Other" segment as part of the DX support business. From the current consolidated fiscal year, these transactions are now recorded under the "school DX" business.

Please note that the segment information for the previous consolidated fiscal year is presented based on the revised classifications.

### 2 Method of calculation for amounts of Net sales, profit or loss, assets, liabilities, and other items by reportable segment

The accounting methods for the reported business segments are generally the same as those adopted in the preparation of the consolidated financial statements.

The profit of the reportable segments is based on operating income. Internal revenues and transfers between segments are based on market prices.

3 Information on amounts of Net sales, profit or loss, assets, liabilities, and other items by reportable segment, and disaggregation of revenue

Previous fiscal year (from October 1, 2023 to September 30, 2024)

(Unit: Thousands of yen)

	Reportable segment					Adjustment (Note) 1	Amounts recorded in the consolidated financial statements (Note) 2
	Content Business	Healthcare Business	School DX Business	Other businesses	Total		
Net sales							
Goods or services transferred at a point in time	16,720,671	5,429,864	1,167,716	3,764,724	27,082,976	-	27,082,976
Goods or services transferred over a certain period	61,203	43,558	45,760	435,663	586,185	-	586,185
Revenue from contracts with customers	16,781,874	5,473,423	1,213,476	4,200,387	27,669,161	-	27,669,161
Net sales to external customers	16,781,874	5,473,423	1,213,476	4,200,387	27,669,161	-	27,669,161
Internal net sales or transfers between segments	152,253	8,448	20,000	1,153,810	1,334,512	(1,334,512)	-
Total	16,934,128	5,481,871	1,233,476	5,354,197	29,003,674	(1,334,512)	27,669,161
Segment profit or loss (-)	4,320,404	352,202	(66,978)	300,092	4,905,720	(2,511,502)	2,394,217
Other items							
Depreciation	935,884	166,068	253,812	37,957	1,393,722	138,212	1,531,935
Amortization of goodwill	176,573	717	-	-	177,291	-	177,291

(Note) 1 The adjustment amount of segment profit or loss (-) of -2,511,502 thousand yen includes elimination of inter-segment transactions of 58,480 thousand yen and company-wide expenses not allocated to each reportable segment of -2,569,982 thousand yen. Company-wide expenses mainly consist of general and administrative expenses not attributable to reportable segments.

2 Segment profit or loss (-) is adjusted to operating income in the consolidated financial statements.

3 Segment assets are not disclosed because assets are not allocated to business segments.

For the fiscal year ending September 30, 2025

(Unit: Thousands of yen)

	Reportable segments					Adjustment (Note) 1	Amounts recorded in the consolidated financial statements (Note) 2
	Content Business	Healthcare Business	School DX Business	Other businesses	Total		
Net sales							
Goods or services transferred at a point in time	17,018,050	6,632,558	1,655,542	3,908,834	29,214,985	-	29,214,985
Goods or services transferred over a certain period	59,331	33,497	234,810	368,316	695,954	-	695,954
Revenue from contracts with customers	17,077,382	6,666,055	1,890,352	4,277,150	29,910,940	-	29,910,940
Net sales to external customers	17,077,382	6,666,055	1,890,352	4,277,150	29,910,940	-	29,910,940
Internal net sales or transfers between segments	236,870	10,107	-	1,262,848	1,509,826	(1,509,826)	-
Total	17,314,252	6,676,163	1,890,352	5,539,999	31,420,766	(1,509,826)	29,910,940
Segment profit or loss (-)	4,270,581	(80,148)	550,380	949,073	5,689,886	(2,743,691)	2,946,195
Other items							
Depreciation	586,914	274,424	295,998	35,250	1,192,587	117,697	1,310,284
Amortization of goodwill	36,449	1,305	-	-	37,755	-	37,755

(Note) 1 The adjustment amount of segment profit or loss (-) of -2,743,691 thousand yen includes elimination of inter-segment transactions of 62,779 thousand yen and company-wide expenses not allocated to each reportable segment of -2,806,470 thousand yen. Company-wide expenses mainly consist of general and administrative expenses not attributable to any reportable segment.

2 Segment profit or loss (-) is adjusted to operating income in the consolidated financial statements.

3 Segment assets are not disclosed because assets are not allocated to business segments.

[Information on Impairment Losses on Non-current Assets by Reportable Segment]

Previous fiscal year (from October 1, 2023 to September 30, 2024)

(Unit: Thousands of yen)

	Reportable segment					Adjustment amount	Amounts recorded in the consolidated financial statements
	Content Business	Healthcare Business	School DX Business	Other businesses	Total		
Impairment losses	222,301	38,729	-	238	261,269	-	261,269

For the fiscal year ending September 30, 2025

There are no applicable items.

(Per share information)

	Prior fiscal year (from October 1, 2023 to September 30, 2024)	For the fiscal year ended September 30, 2025
Net assets per share	280.50 yen	331.86 yen
Basic earnings per share	43.05 yen	61.62 yen
Diluted earnings per share	43.02 yen	61.55 yen

(Note) The basis for the calculation of Basic earnings per share and Diluted earnings per share is as follows.

Item	Prior fiscal year (from October 1, 2023 to September 30, 2024)	For the fiscal year ended September 30, 2025
Basic earnings per share		
Profit attributable to owners of parent	2,363,920 thousand yen	3,404,130 thousand yen
Amount not attributable to common shareholders	- thousand yen	- thousand yen
Profit attributable to owners of parent related to common stock	2,363,920 thousand yen	3,404,130 thousand yen
Average number of common shares	54,913,627 shares	55,247,865 shares
Diluted earnings per share		
Adjustment to profit attributable to owners of parent	-	-
Increase in number of common shares	40,504 shares	57,227 shares
(of which, Subscription rights to shares)	40,504 shares	57,227 shares
Overview of potential shares not included in the calculation of diluted earnings per share due to having no dilutive effect	-	-

(Significant Subsequent Events)

There are no applicable items.